| 1 |
Valibouze C, Speca S, Dubuquoy C, Mourey F, M'Ba L, Schneider L, Titecat M, Foligné B, Genin M, Neut C, Zerbib P, Desreumaux P. Saccharomyces cerevisiae prevents postoperative recurrence of Crohn's disease modeled by ileocecal resection in HLA-B27 transgenic rats. World J Gastroenterol 2023; 29(5): 851-866 [DOI: 10.3748/wjg.v29.i5.851] [Reference Citation Analysis]
|
| 2 |
Farahmandi K, Sulaimany S. Probiotic Effects on Disease Prevention and Treatment. Advances in Probiotics for Health and Nutrition [Working Title] 2023. [DOI: 10.5772/intechopen.109717] [Reference Citation Analysis]
|
| 3 |
Paramera EI, Karathanos VT, Konteles SJ. Yeast cells and yeast-based materials for microencapsulation. Microencapsulation in the Food Industry 2023. [DOI: 10.1016/b978-0-12-821683-5.00002-9] [Reference Citation Analysis]
|
| 4 |
Liu A, Gao W, Zhu Y, Hou X, Chu H. Gut Non-Bacterial Microbiota: Emerging Link to Irritable Bowel Syndrome. Toxins 2022;14:596. [DOI: 10.3390/toxins14090596] [Reference Citation Analysis]
|
| 5 |
Mourey F, Decherf A, Jeanne JF, Clément-Ziza M, Grisoni ML, Machuron F, Legrain-Raspaud S, Bourreille A, Desreumaux P. Saccharomyces cerevisiae I-3856 in irritable bowel syndrome with predominant constipation. World J Gastroenterol 2022; 28(22): 2509-2522 [DOI: 10.3748/wjg.v28.i22.2509] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 6 |
Galica AN, Galica R, Dumitrașcu DL. Diet, fibers, and probiotics for irritable bowel syndrome. J Med Life 2022;15:174-9. [PMID: 35419092 DOI: 10.25122/jml-2022-0028] [Reference Citation Analysis]
|
| 7 |
Nguyen T, Toh M, Lu Y, Ku S, Liu S. Biovalorization of Market Surplus Bread for Development of Probiotic-Fermented Potential Functional Beverages. Foods 2022;11:250. [DOI: 10.3390/foods11030250] [Reference Citation Analysis]
|
| 8 |
Singh RP, Shadan A, Ma Y. Biotechnological Applications of Probiotics: A Multifarious Weapon to Disease and Metabolic Abnormality. Probiotics Antimicrob Proteins 2022;14:1184-210. [PMID: 36121610 DOI: 10.1007/s12602-022-09992-8] [Reference Citation Analysis]
|
| 9 |
Layer P, Andresen V, Allescher H, Bischoff SC, Claßen M, Elsenbruch S, Freitag M, Frieling T, Gebhard M, Goebel-Stengel M, Häuser W, Holtmann G, Keller J, Kreis ME, Kruis W, Langhorst J, Jansen PL, Madisch A, Mönnikes H, Müller-Lissner S, Niesler B, Pehl C, Pohl D, Raithel M, Röhrig-Herzog G, Schemann M, Schmiedel S, Schwille-Kiuntke J, Storr M, Preiß JC, Andus T, Buderus S, Ehlert U, Engel M, Enninger A, Fischbach W, Gillessen A, Gschossmann J, Gundling F, Haag S, Helwig U, Hollerbach S, Karaus M, Katschinski M, Krammer H, Kuhlbusch-Zicklam R, Matthes H, Menge D, Miehlke S, Posovszky MC, Schaefert R, Schmidt-Choudhury A, Schwandner O, Schweinlin A, Seidl H, Stengel A, Tesarz J, van der Voort I, Voderholzer W, von Boyen G, von Schönfeld J, Wedel T; Collaborators:., in Zusammenarbeit mit:., Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM)., Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)., Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV)., Deutsche Gesellschaft für Ernährungsmedizin (DGEM)., Deutsche Gesellschaft für Geriatrie (DGG)., Deutsche Gesellschaft für Innere Medizin (DGIM)., Deutsche Gesellschaft für Naturheilkunde (DGNHK)., Deutsche Gesellschaft für Pathologie und Bundesverband deutscher Pathologen e. V. (DGP/BDP)., Deutsche Gesellschaft für Psychosomatische Medizin und Ärztliche Psychotherapie (DGPM)., Deutsche Gesellschaft für Verhaltensmedizin und Verhaltensmodifikation (DGVM)., Deutsche Schmerzgesellschaft e. V., Deutsches Kollegium für Psychosomatische Medizin (DKPM), Deutsche Gesellschaft für Tropenmedizin und Internationale Gesundheit (DTG)., Gesellschaft für Pädiatrische Gastroenterologie und Ernährung (GPGE)., Deutschen Gesellschaft für Kinder- und Jugendmedizin (DGKJ)., Swiss Society of Neurogastroenterology and Motility (SwissNGM)., Informationsforum für Patient:innen mit Magen-Darm-Erkrankungen (MAGDA). Update S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM) – Juni 2021 – AWMF-Registriernummer: 021/016. Z Gastroenterol 2021;59:1323-415. [PMID: 34891206 DOI: 10.1055/a-1591-4794] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 10 |
McFarland LV, Karakan T, Karatas A. Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. EClinicalMedicine 2021;41:101154. [PMID: 34712929 DOI: 10.1016/j.eclinm.2021.101154] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 11 |
Mondal O, Khanna D, Panwar S, Negi S, Basu S. Systematic Review on Therapeutic Applications of Yeast 'Saccharomyces'. IJSRST. [DOI: 10.32628/ijsrst218226] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 12 |
Leo VV, Viswanath V, Deka P, Zothanpuia, Ramji DR, Pachuau L, Carrie W, Malvi Y, Singh G, Singh BP. Saccharomyces and Their Potential Applications in Food and Food Processing Industries. Fungal Biology 2021. [DOI: 10.1007/978-3-030-67561-5_12] [Reference Citation Analysis]
|
| 13 |
Evangelia L, Karanasou EA, Gazouli M. Gut Microbiome and Gastrointestinal Disorders. Gut Microbiome-Related Diseases and Therapies 2021. [DOI: 10.1007/978-3-030-59642-2_3] [Reference Citation Analysis]
|
| 14 |
Savitri, Lata P. Probiotics for Human Health. Microorganisms for Sustainability 2021. [DOI: 10.1007/978-981-15-6795-7_8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 15 |
Duttaroy AK. Gut microbiota on human health and disease. Evidence-Based Nutrition and Clinical Evidence of Bioactive Foods in Human Health and Disease 2021. [DOI: 10.1016/b978-0-12-822405-2.00006-2] [Reference Citation Analysis]
|
| 16 |
. UEG Week 2020 Poster Presentations. United European Gastroenterol J 2020;8:144-887. [PMID: 33043826 DOI: 10.1177/2050640620927345] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 17 |
Decherf A, Dehay E, Boyer M, Clément-Ziza M, Rodriguez B, Legrain-Raspaud S. Recovery of Saccharomyces cerevisiae CNCM I-3856 in Vaginal Samples of Healthy Women after Oral Administration. Nutrients 2020;12:E2211. [PMID: 32722250 DOI: 10.3390/nu12082211] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 18 |
Jahanshahi M, Maleki Dana P, Badehnoosh B, Asemi Z, Hallajzadeh J, Mansournia MA, Yousefi B, Moazzami B, Chaichian S. Anti-tumor activities of probiotics in cervical cancer. J Ovarian Res 2020;13:68. [PMID: 32527332 DOI: 10.1186/s13048-020-00668-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 19 |
Di Vito M, Bellardi MG, Sanguinetti M, Mondello F, Girolamo A, Barbanti L, Garzoli S, Sabatino M, Ragno R, Vitali A, Palucci I, Posteraro B, Gasbarrini A, Prati GM, Aragona G, Mattarelli P, Bugli F. Potent In Vitro Activity of Citrus aurantium Essential Oil and Vitis vinifera Hydrolate Against Gut Yeast Isolates from Irritable Bowel Syndrome Patients-The Right Mix for Potential Therapeutic Use. Nutrients 2020;12:E1329. [PMID: 32392768 DOI: 10.3390/nu12051329] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 20 |
Gaziano R, Sabbatini S, Roselletti E, Perito S, Monari C. Saccharomyces cerevisiae-Based Probiotics as Novel Antimicrobial Agents to Prevent and Treat Vaginal Infections. Front Microbiol 2020;11:718. [PMID: 32373104 DOI: 10.3389/fmicb.2020.00718] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 21 |
Pech-canul ADLC, Ortega D, García-triana A, González-silva N, Solis-oviedo RL. A Brief Review of Edible Coating Materials for the Microencapsulation of Probiotics. Coatings 2020;10:197. [DOI: 10.3390/coatings10030197] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 22 |
Ramsy N, Michail S. Probiotic Use. Encyclopedia of Gastroenterology 2020. [DOI: 10.1016/b978-0-12-801238-3.66050-6] [Reference Citation Analysis]
|
| 23 |
Gayathri R, Aruna T, Malar S, Shilpa B, Dhanasekar KR. Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an add-on therapy for irritable bowel syndrome. Int J Colorectal Dis 2020;35:139-45. [PMID: 31807856 DOI: 10.1007/s00384-019-03462-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 24 |
Herndon CC, Wang YP, Lu CL. Targeting the gut microbiota for the treatment of irritable bowel syndrome. Kaohsiung J Med Sci 2020;36:160-70. [PMID: 31782606 DOI: 10.1002/kjm2.12154] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 25 |
Liu Y, Tran DQ, Rhoads JM. Probiotics in Disease Prevention and Treatment. J Clin Pharmacol 2018;58 Suppl 10:S164-79. [PMID: 30248200 DOI: 10.1002/jcph.1121] [Cited by in Crossref: 79] [Cited by in F6Publishing: 81] [Article Influence: 19.8] [Reference Citation Analysis]
|
| 26 |
Roman P, Abalo R, Marco EM, Cardona D. Probiotics in digestive, emotional, and pain-related disorders. Behav Pharmacol 2018;29:103-19. [PMID: 29521671 DOI: 10.1097/FBP.0000000000000385] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 27 |
Shapiro J, Bernica J, Hernaez R. Risk of Bias Analysis of Systematic Reviews of Probiotics for Treatment of Irritable Bowel Syndrome. Clin Gastroenterol Hepatol 2019;17:784-5. [PMID: 30012436 DOI: 10.1016/j.cgh.2018.07.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 28 |
Ooi SL, Correa D, Pak SC. Probiotics, prebiotics, and low FODMAP diet for irritable bowel syndrome - What is the current evidence? Complement Ther Med 2019;43:73-80. [PMID: 30935559 DOI: 10.1016/j.ctim.2019.01.010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 29 |
Camilleri M. Management Options for Irritable Bowel Syndrome. Mayo Clin Proc 2018;93:1858-72. [PMID: 30522596 DOI: 10.1016/j.mayocp.2018.04.032] [Cited by in Crossref: 54] [Cited by in F6Publishing: 35] [Article Influence: 10.8] [Reference Citation Analysis]
|
| 30 |
Roussel C, Sivignon A, de Vallée A, Garrait G, Denis S, Tsilia V, Ballet N, Vandekerckove P, Van de Wiele T, Barnich N, Blanquet-diot S. Anti-infectious properties of the probiotic Saccharomyces cerevisiae CNCM I-3856 on enterotoxigenic E. coli (ETEC) strain H10407. Appl Microbiol Biotechnol 2018;102:6175-89. [DOI: 10.1007/s00253-018-9053-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 31 |
Hungin APS, Mitchell CR, Whorwell P, Mulligan C, Cole O, Agréus L, Fracasso P, Lionis C, Mendive J, Philippart de Foy JM, Seifert B, Wensaas KA, Winchester C, de Wit N; European Society for Primary Care Gastroenterology. Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus. Aliment Pharmacol Ther 2018;47:1054-70. [PMID: 29460487 DOI: 10.1111/apt.14539] [Cited by in Crossref: 77] [Cited by in F6Publishing: 76] [Article Influence: 15.4] [Reference Citation Analysis]
|
| 32 |
Rodiño-Janeiro BK, Vicario M, Alonso-Cotoner C, Pascua-García R, Santos J. A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies. Adv Ther 2018;35:289-310. [PMID: 29498019 DOI: 10.1007/s12325-018-0673-5] [Cited by in Crossref: 106] [Cited by in F6Publishing: 117] [Article Influence: 21.2] [Reference Citation Analysis]
|
| 33 |
Gabrielli E, Pericolini E, Ballet N, Roselletti E, Sabbatini S, Mosci P, Decherf AC, Pélerin F, Perito S, Jüsten P, Vecchiarelli A. Saccharomyces cerevisiae-based probiotic as novel anti-fungal and anti-inflammatory agent for therapy of vaginal candidiasis. Benef Microbes 2018;9:219-30. [PMID: 29380641 DOI: 10.3920/BM2017.0099] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 34 |
Fuke N, Aizawa K, Suganuma H, Takagi T, Naito Y. Effect of combined consumption of Lactobacillus brevis KB290 and β-carotene on minor diarrhoea-predominant irritable bowel syndrome-like symptoms in healthy subjects: a randomised, double-blind, placebo-controlled, parallel-group trial. Int J Food Sci Nutr 2017;68:973-86. [PMID: 28391736 DOI: 10.1080/09637486.2017.1311843] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 35 |
Dimidi E, Rossi M, Whelan K. Irritable bowel syndrome and diet: where are we in 2018? Curr Opin Clin Nutr Metab Care 2017;20:456-63. [PMID: 28872467 DOI: 10.1097/MCO.0000000000000416] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 36 |
Harris LA, Baffy N. Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome. Postgrad Med 2017;129:872-88. [PMID: 28936910 DOI: 10.1080/00325481.2017.1383819] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 7.3] [Reference Citation Analysis]
|
